Summary
The AI-generated response does not evaluate the provided AIRSUPRA prescribing information against the user’s multiple non-label claims (generic availability, patent/exclusivity searches, interchangeability criteria, insurance coverage, etc.). It only includes a single label-matching claim that is not present in the user’s listed claims.
Category Scores
Accurate Statements
AIRSUPRA is indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older.
Supported by Section 1 (INDICATIONS AND USAGE): “...as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older.”
Unsupported Statements
The response evaluates the user’s claims about generic availability/interchangeability/patent landscape/insurance coverage and concludes “PASS” for AIRSUPRA’s indicated use.
Those topics are not addressed in the supplied label sections; the response does not provide label-based evaluation for the listed non-label claims.
The response’s references to “dose limit” and “as needed” dosing safety are part of the evaluation for the user’s non-label generic/interchangeability queries.
The user’s provided claims focus on generic branding and substitution practices, which are not supported or contradicted by the extracted label content.
“Not applicable... the claim concerns only the approved adult indication wording.”
This statement is not verifiable from the provided user claims; the response does not clearly scope its evaluation to only the single indication sentence.
Contradictions
Important Omissions
No label-based assessment was provided for the user’s generic/interchangeability claims (e.g., whether an “Airsupra generic” exists, criteria for substitution, insurance tier coverage, or use of patent tools).
Importance:
High
No evaluation of labeling elements relevant to medication substitution accuracy (dose/actuation equivalence, priming instructions, maximum daily dose, contraindications, warnings/precautions) as they would apply to the asserted substitution/generic equivalence claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Because the response primarily asserts label-supported indication language and does not provide actionable guidance about substitution or generics, direct patient risk from incorrect label content appears limited; however, failure to evaluate substitution-related claims against the label could indirectly mislead.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
The AI response did not meaningfully assess the user’s listed generic/interchangeability/patent/insurance claims against the supplied FDA label text; it only included a single label-supported indication statement not tied to the user claims.
Suggested Improvement
Limit evaluation to statements that are actually supported/contradicted by the provided AIRSUPRA label excerpts, and for substitution/generic-equivalence claims cite relevant label details (e.g., active ingredients per actuation, dosage regimen, maximum daily dose, priming/administration instructions) rather than making unverifiable assertions about generic availability or interchangeability criteria.